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Abstract
Purpose of Review There is an established association be-
tween hypertension and increased risk of poor cognitive per-
formance and dementia including Alzheimer’s disease; how-
ever, associations between antihypertensive medications
(AHM) and dementia risk are less clear. An increased interest
in AHM has resulted in expanding publications; however,
none of the recent reviews provide comprehensive review.
Our extensive review includes 24 mechanistic animal and hu-
man studies published over the last 5 years assessing relation-
ship between AHM and cognitive function.
Recent Findings All classes of AHM showed similar result
patterns in animal studies. Themechanism bywhich AHMexert
their effect was extensively studied by evaluating well-
established pathways of AD disease process, including amyloid
beta (Aβ), vascular, oxidative stress and inflammation pathways,
but only few studies evaluated the blood pressure lowering effect
on the AD disease process.
Summary Methodological limitations of the studies prevent
comprehensive conclusions prior to further work evaluating
AHM in animals and larger human observational studies, and
selecting those with promising results for future RCTs.
Keywords Antihypertensivemedication .Cognitive decline .
Dementia . Alzheimer’s disease
Introduction
Alzheimer’s disease (AD), the most common cause of de-
mentia [1], is characterized by extracellular amyloid beta
(Aβ) deposition in the form of neuritic plaques, intracellular
deposition of hyperphosphorylated microtubule-associated
tau protein which culminates in synaptic loss, neuronal cell
death, Aβ angiopathy, oxidative stress, and inflammatory
processes resulting in cognitive impairment [2]. However,
the exact mechanisms are still unclear.
There is a long established association between hypertension
and increased risk of cognitive decline and AD in humans [3],
but the potential association between antihypertensive treatment
and reduced risk of AD has been harder to determine. Attempts
to understand possiblemechanisms have shifted attention toward
the potential pleiotropic effects of the different classes of antihy-
pertensive medication (AHM) and their potential impact on cog-
nitive function [4, 5]. As a result, there are an increasing number
of animal studies evaluating AHM, such as AHMacting through
renin angiotensin system or altering calcium homeostasis.
This review aims to provide such an update in two parts.
Part 1 provides an overview of the recent human observational
and clinical trial literature, and part 2 reviews the recent phys-
iological and animal work.
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The databases Embase, PsycINFO®, Medline, Medline in
process, and other nonindexed citations and PubMed were
searched from 2010 to February 2016 using the search terms:
dementia or cognit* or mild cognitive impairment, and anti-
hypertensives, or antihypertensive agents, or diuretic or di-
uretics or thiazide-like or calcium channel blocker or calcium
channel blockers or calcium antagonist or angiotensin
converting enzyme inhibitor or angiotensin-converting en-
zyme inhibitors or ACE inhibitors or angiotensin receptor
blocker or angiotensin receptor blockers or angiotensin recep-
tor blockers (ARB) or beta blocker or adrenergic beta-antag-
onists. Where review articles were identified, reference lists
were searched for original research articles published within
the last 5 years.
Inclusion and Exclusion Criteria
Included animal or mechanistic studies required exposure to
one of the antihypertensive classes of interest, calcium chan-
nel blockers (CCB), ARB, angiotensin converting enzyme
inhibitors (ACE-I), beta blocker (BB), and diuretics, and to
have a control or comparator group; however, a specific out-
come measure was not required.
Article Selection
Abstracts were double read by SY and MS. Discrepancies
were resolved by discussion. Full text articles were double
read by the same team and data extracted into standard tables,
collated by antihypertensive class.
Results
Animal and Human Mechanism Studies
Searches retrieved 138 PubMed records and 522 records from
Medline, PsycINFO® and Embase. Of these, seven were re-
view articles [6–12], 19 articles presented results from animal
studies exploring mechanisms [13–31], and there were five
human studies of which one was an autopsy study [32], two
human cerebrospinal fluid (CSF) studies [33, 34], one small
RCT [35], and one in vivo human cell study [36].
The methodology of the 19 animal studies varied widely in
the selection of animals and drugs used, length of treatment
times, and outcomes. Animal models ranged from mouse
models using wild-type mice [13, 23], aged Swiss mice [31],
wild-type mice treated with icv amyloid beta 25–35 to be used
as an AD mouse model [27], and transgenic (Tg) AD mice
alone [17, 19, 21, 29, 30], to rat models such as Wistar [18,
20], Sprague-Dawley [16, 22], or spontaneously hypertensive
rats (SHR) [14, 15, 24, 26, 28]. Regarding AHM used, 17 of
the 19 studies used CCB, ACE-I, or ARB alone or in combi-
nation. Commercially available ACE-Is used were captopril
[17, 18, 29], enalapril [27], imidapril [27], lisinopril [14],
perindopril [26, 27], and trandolapril [19]. ARBs used includ-
ed losartan [18, 19, 25], olmesartan [24], telmisartan [15, 22,
28], and valsartan [14]. The renin inhibitor aliskiren was used
in one study [13]. CCBs used included azelnidipine [24],
isradipine [20, 30], lercanidipine [14], nicardipine [14, 16,
19, 20, 30], nifedipine [30], nimodipine [16, 20, 22, 30], and
a nonselective CCB flunarizine [31]. Other antihypertensives
included BBs such as carvedilol and propranolol [19], di-
uretics such as amiloride and furosemide [19], and hydral-
azine [14, 19]. Experimental drugs such as angiotensin II
[18], PD-123177 (angiotensin 2 receptor blocker) [20], and
ICI 11,551 (a selective beta 2 receptor antagonist) [21] were
also used. One study did not use antihypertensive medication
[23]. One of the five identified human studies reported use of
telmisartan and amlodipine [35], while four studies compared
ARB users with other AHMs [32–34, 36]. Comparators used
differed, as did the length of treatment times, which varied
between 4 days and 15 months.
Outcome measures ranged from cognitive tests to bio-
markers. Cognitive measures included water maze [15, 16,
19–21, 25, 26, 31], Y maze [13, 18], object recognition
[21, 27], passive avoidance [18], open field [15, 22], and
spontaneous alternation [27] tests. Locomotor function was
assessed in five studies [22, 24, 26, 27, 31]. Numerous
studies used serum, cerebrospinal fluid, or histopathologi-
cal measures of amyloid beta and/or tau levels as their
outcome [17, 19, 21, 23, 25, 29, 30]. Additional histopath-
ological measures included pyramidal neurons in hippo-
campus [14], hippocampus morphology [16], and vascular
pathology [24, 25]. Alteration in markers of oxidative
stress [13, 18, 22, 24–26, 31], inflammation [13, 16, 22,
24, 26], apoptosis [20, 26], brain-derived neurotrophic fac-
tor (BDNF), and alpha tubulin levels [15] were also fre-
quently used alone or in conjunction with cognitive mea-
sures. Some studies included measurement of various pro-
teins of the renin angiotensin system (RAS) in the brain as
their outcomes [13, 23, 25–27, 30]. Outcomes included
infarct size [24, 31] and cerebral blood flow [13, 16, 24,
25] in studies evaluating the effect of antihypertensive
medication in cerebral ischemia models. Surprisingly, only
seven studies included blood pressure measurements as
their outcome [13–15, 19, 24, 26, 28]. Human study out-
comes also varied and included AD and vascular pathology
in one autopsy study [32], amyloid and tau levels in cere-
brospinal fluid (CSF) [33, 34], cognitive measures [36],
and, in the small RCT, blood pressure measurements and
cognitive outcomes [35].
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CCB
One human study reporting on the effect of CCB use found
that of the 167 AHM users, only nifedipine users had signif-
icantly lower Aβ levels when compared to 107 matched
AHM never users [36] (Table 1).
Eight animal studies reported results of treatment with
CCB alone [14, 16, 19, 20, 30, 31] or in combination with
ARB [22, 23]. Azelnidipine decreased blood pressure, infarct
size, and also reduced markers of oxidative stress and inflam-
mation [24]. The nonselective CCB flunarizine reversed im-
pairment in learning, memory, and motor function after cere-
bral ischemia and reversed cerebral ischemia-associated de-
crease in anti-oxidative stress markers [31]. Isradipine in-
creased angiogenesis [30] and improved memory acquisition
[20]. Lercanidipine decreased blood pressure and protected
against neuronal death [14]. Nicardipine reduced Aβ1–42
and Aβ1–40 in the brain [19] and increased angiogenesis
[30], but did not improve cognition [19]. Nifedipine increased
angiogenesis [30]. Nimodipine improved regional cerebral
blood flow and protected hippocampal morphology [16], re-
duced inflammatory markers [16], increased angiogenesis
[30], improved memory acquisition [20], and prevented learn-
ing impairment in animals with cerebral ischemia [16]
(Table 1).
ACE-I
Themost extensively studied ACE-I was captopril, which was
associated with genetic upregulation of proteins associated
with neuronal function and membranes [17], reduced Aβ bur-
den in the brain [17], decreased conversion of Aβ1–43 to
Aβ1–42 [28], increased anti-oxidative stress markers [18],
decreased oxidative stress markers [17], and better perfor-
mance on learning and memory tasks [18]. Captopril treat-
ment also inhibited ACE activity and decreased angiotensin
II levels [17, 29]. Lisinopril did not protect against neuronal
death even with significant blood pressure reduction [14].
Perindopril and enalapril inhibited plasma ACE activity by
90 % but only perindopril inhibited brain ACE activity by
50 % [27]. Perindopril decreased blood angiotensin II levels
[26] and also levels of oxidative stress markers [26].
Perindopril improved memory function [26]. Trandalopril
treatment reduced Aβ burden in the brain [19] (Table 2).
ARB
Losartan decreased angiotensin 1 and 4 receptor levels in the
brain [25] and improved cerebral blood flow [25]. In one
study, it decreased Aβ1–42 [19], while in another, it did not
alter Aβ1–42 in the brain [25]. Treatment with losartan also
resulted in better performance on learning and memory tasks
[18, 25]. Telmisartan improved cerebral blood flow in humans
[35], reduced neurologic deficits and improved locomotor
function after cerebral ischemia [22, 35], reduced inflamma-
tory and oxidative stress markers [22], reduced low-density
receptors and apolipoprotein E expression in the brain [28],
and increased BDNF levels in the hippocampus [15].
Treatment with telmisartan resulted in better performance on
learning and memory tasks in animals [15]; however, there
was no improvement in memory in people [35]. Olmisartan
did not reduce blood pressure but reduced infarct size in cere-
bral ischemia and inflammatory markers [24]. Valsartan re-
duced blood pressure but did not protect against neuronal
death [14] (Table 2).
ARBs were studied as a class in human studies. One brain
autopsy study showed that ARB use was associated with sig-
nificantly lower AD pathology, while no alteration of vascular
pathology was observed when compared to other or no anti-
hypertensive medication users [32]. Additionally, it was found
that ARB use in people with normal cognition or mild cogni-
tive impairment (MCI) was associated with lower levels of tau
and phosphorylated tau [32, 34] and higher levels of Aβ1–42
in cerebrospinal fluid [34], and with decreased risk of demen-
tia [34] when compared to other antihypertensive medication
users (Table 2).
Diuretics
Only one animal study evaluated a diuretic, furosemide, and
found that it reduced brain Aβ1–42 without affecting blood
pressure [19].
BBs
Two animal studies reported on the effect of BB use (Table 3).
Treatment with nonselective beta adrenergic receptor
blockers, carvedilol and propranolol, resulted in decreased
brain Aβ1–40 and Aβ1–42 levels; however, this did not trans-
late into improved cognition [19]. Carvedilol reduced Aβ1–
42 in the brain without affecting blood pressure [19]. In con-
trast, treatment with a selective beta 2 adrenergic receptor
(β2AR) antagonist resulted in significantly worse working
memory and increased amyloid plaque burden, Aβ1–42
levels, tau phosphorylation, and accumulation in the hippo-
campus, suggesting involvement of β2ARs in the amyloid
pathway and in cognitive function [21].
Discussion
The importance of dementia as a clinical and public health
issue is rapidly increasing as the population ages [37]. Thus,
identifying new and effective approaches to prevention or
treatment is critical. Due to the lengthy process of developing
new medications, there has been a recent surge in interest
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toward re-purposing currently available medications for the
treatment of AD, including AHM. In this paper, we provide
an extensive review of 24 mechanistic animal and human
studies published over the last 5 years assessing the relation-
ship between AHM and cognitive function.
Previous studies have shown a possible protective effect of
certain AHM against AD risk [1], and it has been suggested
that this protective effect is independent of, or in addition to,
the blood pressure lowering effect [4, 5]. It is therefore not
surprising that the mechanistic studies have focused on eval-
uating effects of AHM on well-established pathways in the
AD disease process, including Aβ, vascular, oxidative stress,
and inflammation pathways [2].
Of the six CCBs, nimodipine has been the most widely
studied, and it was associated with angiogenesis and neuropro-
tection in the hippocampus, reduced inflammation, and im-
proved cognitive function, but not with improved cerebral
blood flow. Flunarizine and isradipine also improved cognition
and had some effect on some of the abovementioned pathways.
Of the five ACE-Is studied, most studies evaluated effects
of captopril and perindopril. Captopril was associated with
neuroprotection [17], reduced Aβ burden in the brain [17,
29], decreased oxidative stress [17, 18], and better cognitive
performance [18]. This effect was mediated by alteration of
ACE activity and angiotensin II levels in the brain [17, 29].
Perindopril was associated with decreased oxidative stress
[26] and improved cognitive function [26] and was shown
to inhibit ACE activity in both blood and the brain ACE
[27]. These findings suggest the beneficial effect of ACEs
when crossing the blood-brain barrier; however, a previ-
ous observational study by Sink et al. did not support this
hypothesis [38].
Of the four ARBs studied, losartan and telmisartan were
examined in detail. Losartan use was associated with improved
cerebral blood flow [25]. Yet, its effect on Aβ1–42 was equiv-
ocal with one study showing decreased levels [19], while an-
other unchanged levels of Aβ1–42 [25]. Treatment with
losartan also resulted in better performance on learning and
memory tasks [18, 25]. These findings suggest beneficial effect
via vascular rather than amyloid pathways, which is supported
by its angiotensin 1 and 4 receptor lowering effect in the brain
[25]. The other medication evaluated in detail was telmisartan,
which, similar to losartan, was associated with improved cere-
bral blood flow in humans [35], reduced inflammation, oxida-
tive stress [22], and markers of brain lipid metabolism [28].
Telmisartan also improved cognitive performance in animals
[15], however, not in humans [35]. This negative finding in
humans was replicated in a large multinational double-blind
randomized placebo controlled trial, TRANSCEND, compar-
ing ARB (telmisartan) use to placebo [3].
Previous animal studies and also RCTs with AHM have
shown that blood pressure reduction, particularly in close prox-
imity to development of cognitive impairment, does not alter
dementia risk. Additionally, it is possible that treatment comes
too late to mitigate the injury related to chronic exposure, sug-
gesting an earlier window of benefit after which neural damage
is hard to remediate. Thus, other mechanisms involved in AD
development should to be explored. Medications explored in
mechanistic studies have been different agents to those used in
RCTs.
Conclusions
Similar to human observational studies and RCTs, different
classes of AHM show similar result patterns in animal studies.
Inconsistencies in the sources of evidence from the use of
different animal types, ages, treatment times, and outcome






















































ANOVA -Significantly better performance on Morris
water maze in non-Tg-AD mice treated
with NaCl, while worse in non-Tg mice
treated with ICI, and non-Tg mice treated
with NaCl, and worse when treated with
ICI
-Aβ42 and tau levels in hippocampus of
ICI-treated 3xTg-AD mice was signifi-
cantly higher than when treated with
NaCl suggesting increased Aβ produc-
tion
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measures limit the possibility of drawing firmer conclusions.
Similar to observational studies, the relative lack of informa-
tion on blood pressure levels is a major limitation. These lim-
itations restrict our ability to draw wider ranging conclusions
about use of specific antihypertensive classes, subclasses, or
individual drugs. However, AHM that have had promising
results in animals and larger human observational studies
should be selected for future RCTs.
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